The results of phase 2 study FIGHT-202 and FDA approval of pemigatinib in 2020 as the first FGFR1–3 inhibitor in the treatment of advanced intrahepatic cholangiocarcinoma with FGFR2 fusions or arrangements have led to improvements in the therapeutic strategies of this tumor entity [5, 6]. Here, FGFR2 is linked to neoplasm.